Literature DB >> 28155628

Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges.

Grigorios G Dimas1, Triantafyllos P Didangelos2, Dimitrios M Grekas2.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) are zinc-dependent proteases that degrade components of the extracellular matrix (ECM). In glomerular disease, MMPs are major regulators of ECM degradation as well as structural and functional integrity in the glomerulus. In altered matrix composition diseases, glomerular damage is due to increased degradation of kidney and vessel basement membranes (BMs) by MMPs. MMP -2 and -9 are both considered as the main enzymes that degrade collagen type-IV (coll-IV), which represents the key collagenous component of ECM and constitutes the architectural structure of vessels and glomerular BM. There is growing evidence implicating MMPs in atherosclerosis as well as in cardiovascular disease (CVD) and chronic kidney disease (CKD). Specific endogenous tissue inhibitors of MMPs (TIMPs) are also implicated in CKD, CVD and diabetic nephropathy (DN).
CONCLUSION: The present review discusses the role of MMPs -2 and -9 in DN, as a leading cause of endstage renal disease and as a model of the link between progressive glomerulosclerosis and MMP expression. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Matrix metalloproteinases; atherosclerosis; diabetic nephropathy; gelatinases; glomerulosclerosis; proteinuria

Mesh:

Substances:

Year:  2017        PMID: 28155628     DOI: 10.2174/1570161115666170202162345

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  8 in total

1.  YKL-40 promotes the progress of atherosclerosis independent of lipid metabolism in apolipoprotein E-/- mice fed a high-fat diet.

Authors:  Lei Chen; Jianlei Zheng; Qi Xue; Yan Zhao
Journal:  Heart Vessels       Date:  2019-05-21       Impact factor: 2.037

Review 2.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic kidney disease and acute kidney injury: a systematic review of the literature.

Authors:  C L Sampieri; R A Orozco-Ortega
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

3.  Matrix metalloproteinase-1 and -2 as markers of mineral bone disease in chronic kidney disease patients.

Authors:  K Thisiadou; V Liakopoulos; G Dimas; G Koliakos; M Karamouzis
Journal:  Hippokratia       Date:  2017 Jan-Mar       Impact factor: 0.471

4.  Epigenetic Regulation of the N-Terminal Truncated Isoform of Matrix Metalloproteinase-2 (NTT-MMP-2) and Its Presence in Renal and Cardiac Diseases.

Authors:  Juliana de Oliveira Cruz; Alessandra O Silva; Jessyca M Ribeiro; Marcelo R Luizon; Carla S Ceron
Journal:  Front Genet       Date:  2021-02-25       Impact factor: 4.599

5.  Lysyl oxidases expression and histopathological changes of the diabetic rat nephron.

Authors:  Jun Chen; Jie Ren; Wings T Y Loo; Liang Hao; Min Wang
Journal:  Mol Med Rep       Date:  2017-11-29       Impact factor: 2.952

6.  Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy.

Authors:  Massimo Dal Monte; Maurizio Cammalleri; Valeria Pecci; Monica Carmosino; Giuseppe Procino; Alessandro Pini; Mario De Rosa; Vincenzo Pavone; Maria Svelto; Paola Bagnoli
Journal:  J Cell Mol Med       Date:  2018-11-13       Impact factor: 5.310

Review 7.  Hydrogen Sulfide: Recent Progression and Perspectives for the Treatment of Diabetic Nephropathy.

Authors:  Hai-Jian Sun; Zhi-Yuan Wu; Lei Cao; Meng-Yuan Zhu; Teng-Teng Liu; Lei Guo; Ye Lin; Xiao-Wei Nie; Jin-Song Bian
Journal:  Molecules       Date:  2019-08-06       Impact factor: 4.411

8.  Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid.

Authors:  Verena Hugenberg; Malte Behrends; Stefan Wagner; Sven Hermann; Michael Schäfers; Hartmuth C Kolb; Katrin Szardenings; Joseph C Walsh; Luis F Gomez; Klaus Kopka; Günter Haufe
Journal:  EJNMMI Radiopharm Chem       Date:  2018-07-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.